

## **Hepatitis E vaccine**

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2716888/>

Published online 2008 Apr 10. doi: 10.1007/s12072-008-9071-4

PMCID: PMC2716888, PMID: 19669259

### **Cited in:**

Hepatol Int. 2008 Sep; 2(3): 308–315.

### **Hepatitis E vaccine**

Rakesh Aggarwal<sup>1</sup> <sup>1</sup>Department of Gastroenterology, Sanjay Gandhi Postgraduate Institute of Medical Sciences (SGPGIMS), Rae Bareilly Road, Lucknow, 226 014 India

Shahid Jameel<sup>2</sup> <sup>2</sup>Virology Group, International Centre for Genetic Engineering and Biotechnology (ICGEB), Aruna Asaf Ali Marg, New Delhi, 110 067 India

### **Abstract**

Hepatitis E is an emerging disease in resource-poor regions of the world. It is estimated that about 2 billion people live in areas endemic for this disease. The inability to reproducibly culture hepatitis E virus makes it impossible to develop traditional live or inactivated vaccines. However, significant progress has been made in developing and testing recombinant subunit vaccines based on the viral capsid protein. This review summarizes these efforts.

**Keywords:** Hepatitis, Hepatitis E, HEV, Vaccine

### **References**

20. Joshi Y, Babu S, Sarin S, Tandon BN, Gandhi BM, Chaturvedi VC. Immunoprophylaxis of epidemic non-A non-B hepatitis. Indian J Med Res 1985;81:18–19. [PubMed]